Zal Bilimoria simply raised a $50M fourth Refactor Capital fund, and nonetheless relishes his solo GP standing

Zal Bilimoria has been a solo basic associate since 2018, and has no plans to cease. And he credit the choice to former colleague, David Lee, who began Refactor Capital with him in 2016.

He mentioned that he wouldn’t have been capable of begin the Burlingame-based agency with out Lee, a former Google govt who ran Ron Conway’s seed-stage enterprise fund SV Angel for a number of years. Collectively, they raised an preliminary $50 million fund. When Lee determined to retire in 2018, he needed Bilimoria to stick with Refactor as a solo GP. 

Being a solo GP means having full authority to make funding choices alone whereas additionally having full accountability for issues like fundraising. And whereas that stage of freedom may sound fantastic, it additionally signifies that there aren’t any vested companions to seek advice from, who push again and make a VC scrutinize funding choices in methods that will not have occurred to them. Whereas angel traders do that, they’re spending their very own cash. A sole investor is investing on behalf of restricted companions who’re entrusting that this individual will make their cash develop.

“He satisfied me to remain solo, and that was at a time when solo GPs weren’t in vogue,” Bilimoria instructed TechCrunch. “He instructed me that since I like my independence and authority and love spending time with founders, I ought to keep solo. I used to be tremendous nervous, however the extra I spent desirous about it and speaking to people, I spotted that was going to be what I needed to do, and I’ve not regarded again. I’m going to be a solo GP for the remainder of my profession, if I will help it.”

Bilimoria isn’t with out his personal distinctive pedigree. Earlier than becoming a member of Refactor, Bilimoria spent practically three years as a associate at Andreessen Horowitz, the place he helped get the agency’s $200 million Bio Fund off the bottom. Previous to a16z, Bilimoria spent a decade constructing tech merchandise at tech giants, together with Google, Netflix, LinkedIn and Microsoft. He was additionally the founding father of client cell startup Sniply.

With Refactor, he’s investing in firms “fixing the largest challenges dealing with society,” he mentioned. In truth, the time period “refactor” comes from pc science and refers to creating code extra environment friendly.

And being a solo GP hasn’t slowed Bilimoria a bit. He went on to lift three further funds and has now closed a fourth fund of $50 million in capital commitments to spend money on the areas of biotech, local weather and exhausting tech startups.

Since its 2016 launch, Refactor has invested in over 100 firms, of which 4 have gone on to develop into unicorns, together with Solugen, which is utilizing artificial biology to take hydrocarbons out of the chemical compounds trade and Astranis, which is making micro satellites. 

Final week, Solugen obtained a $214 million mortgage from the Division of Vitality Mortgage Applications Workplace to construct their subsequent Solugen Bioforge in Minnesota that can make chemical compounds from corn sugar somewhat than petroleum. Awarded to a small variety of startups, the DOE awarded an identical mortgage to Tesla in 2010.

Bilimoria was capable of increase the brand new fund in lower than 90 days, he mentioned. Ninety % of the fund was raised by current restricted companions, together with corporations like Knollwood Funding Advisory. A majority LPs are institutional traders, and the complete LP group is U.S. traders.

“I really feel very fortunate to have this LP group,” he mentioned. “I used to be chasing one institutional investor for the final 4 funds, and I lastly acquired them into this fund, so that they’re a part of my new 10%.”

Bilimoria is wrapping up investments from the third fund, however has already dedicated some capital from the fourth fund. 

This new fund will proceed to guide pre-seed and seed investments into startups working in areas, together with novel battery applied sciences, most cancers therapies, IVF developments and chemical compounds. Verify sizes are usually $1 million to $2 million, and can be cut up between 20 and 25 firms over the subsequent three years, Bilimoria mentioned.